Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Co-morbid illnesses or other concurrent disease which, in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would interfere significantly with whole-breast irradiation (such as connective tissue disorders, lupus, or scleroderma)
Any of the following co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens:* History of myocardial infarction* Unstable angina* Left ventricular hypertrophy* Mitral valve prolapse syndrome
Any serious active disease or co-morbid condition, which in the opinion of the principal investigator, will interfere with the safety or compliance of the trial
Any condition which in the investigators opinion makes the subject unsuitable for study participation
Recent extended history of constant-recurrent substance abuse or another medical condition that might compromise safety or the successful completion of the study
Any other medical condition that in opinion of investigator would place patient at increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent or serious thromboembolic events)
Patients must have progressed (in the opinion of the treating investigator) following the most recent line of therapy
Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to < 1 year, or confound data interpretation
Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patients participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
Patients must not have any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the study drug
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patients risk, interfere with the patients participation in the study, or hinder evaluation of study results
Any other medical or psychiatric condition that in the opinion of the investigator would make the study therapy unsafe for the patient
Any condition that, in the opinion of the treating investigator would interfere with evaluation of the investigational product or interpretation of subject safety or study results
Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical disorder that would interfere with the patients safety
Current life-threatening illness, medical condition, or organ system dysfunction, which, in the investigators opinion, could compromise the patients safety, or put the study at risk
Patients with any condition that in the judgment of the investigator would jeopardize safety or patient compliance with the protocol
Co-morbid illnesses or other concurrent disease that, in the judgement of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow-up
No known medical condition (e.g. a condition associated with uncontrolled diarrhea such as ulcerative colitis or acute diverticulitis) that, in the investigators opinion, would increase the risk associated with study participation or interfere with the interpretation of safety results
Patients for whom it is not in the best interest to participate in the study, in the opinion of the treating investigator
Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational treatment or interpretation of patient safety or study results
